Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of HEC83518 in Healthy Chinese Subjects
NCT04667429Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Jan 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HEC-83518 in Insomnia (5 arms), sponsored by Sunshine Lake Pharma. Primary endpoint: Adverse event up to 34 days. Started Jan 2021; status: completed.
02
Drugs
HEC-83518
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT04667429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04667429.